Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and predisposes to an increased risk of thromboembolic events. Patients affected by AF exhibit an increased risk of stroke compared with those in sinus rhythm, with the most common location of thrombi in the left atrial appendage. Until 2009, warfarin and other vitamin K antagonists were the only class of oral anticoagulants available. More recently, dabigatran, rivaroxaban, apixaban, and edoxaban have been approved by regulatory authorities for prevention of stroke in patients with non-valvular AF. Few data are available about the efficacy of novel oral anticoagulants for the treatment of left atrial and left atrial appendage thrombosis. Aim of this review is to summarize available evidence regarding the effectiveness of novel oral anticoagulants on left atrial appendage thrombosis.
Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
Fabio
F
Marsico
Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
Milena
M
Cecere
Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
Antonio
A
Parente
IRCCS SDN, Istituto di Ricerca, Naples, Italy.
Stefania
S
Paolillo
Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
Fabiana
F
de Martino
Villa dei Fiori, Acerra, Naples, Italy.|Mount Sinai Medical School, New York, USA.
Santo
S
Dellegrottaglie
Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
Bruno
B
Trimarco
Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy. fpperron@unina.it.
Pasquale
P
Perrone Filardi
D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D020517:Atrial Appendage / Q000473:pathology*; D001281:Atrial Fibrillation / Q000150:complications; D006325:Heart Atria / Q000473:pathology*; D006801:Humans; D020521:Stroke / Q000517:prevention & control; D013927:Thrombosis / Q000188:drug therapy*
D000925:Anticoagulants
Atrial fibrillation; Left atrial appendage thrombus; Novel oral anticoagulants; Stroke